The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

被引：1
|
作者：
Tripathy, Sambit [1 ]
机构：
[1] AIIMS, Dept Urol, Bhubaneswar, Odisha, India
来源：
INDIAN JOURNAL OF UROLOGY | 2021年 / 37卷 / 03期
关键词：
D O I：
10.4103/iju.IJU_542_20
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [21] Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
    Jiang, Shan
    Terasawa, Emi
    Horton, Viviana Garcia
    Ayyagari, Rajeev
    Waldeck, A. Reginald
    Halabi, Susan
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
    Shore, Neal D.
    Gratzke, Christian
    Feyerabend, Susan
    Werbrouck, Patrick
    Carles, Joan
    Vjaters, Egils
    Tammela, Teuvo L. J.
    Morris, David
    Aragon-Ching, Jeanny B.
    Concepcion, Raoul S.
    Emmenegger, Urban
    Fleshner, Neil
    Grabbert, Markus
    Lietuvietis, Vilnis
    Mahammedi, Hakim
    Cruz, Felipe M.
    Paula, Adriano
    Pieczonka, Christopher
    Rannikko, Antti
    Richardet, Martin
    Silveira, Glauco
    Kuss, Iris
    Le Berre, Marie-Aude
    Verholen, Frank
    Sarapohja, Toni
    Smith, Matthew R.
    Fizazi, Karim
    ONCOLOGIST, 2024, 29 (07): : 581 - 588
  • [23] Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
    Rhea, Logan P.
    Gupta, Brinda
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (02) : 107 - 108
  • [24] Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer
    Mori, Keiichiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (03) : 430 - 431
  • [25] Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer
    Mason, Malcolm
    EUROPEAN UROLOGY, 2018, 74 (06) : 845 - 845
  • [26] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Schultz, Neil M.
    O'Day, Ken
    Sugarman, Rebecca
    Ramaswamy, Krishnan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 538 - 549
  • [27] Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
    Pang, J. S-T.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Uemura, Hiroji
    Matsushima, Hisashi
    Kobayashi, Kazuki
    Mizusawa, Hiroya
    Nishimatsu, Hiroaki
    Fizazi, Karim
    Smith, Matthew
    Shore, Neal
    Tammela, Teuvo
    Tabata, Ken-ichi
    Matsubara, Nobuaki
    Iinuma, Masahiro
    Uemura, Hirotsugu
    Oya, Mototsugu
    Momma, Tetsuo
    Kawakita, Mutsushi
    Fukasawa, Satoshi
    Kobayashi, Tadahiro
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Suzuki, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 578 - 590
  • [29] Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
    Beer, Tomasz M.
    Saad, Fred
    Sternberg, Cora N.
    Hussain, Maha H. A.
    Ganguli, Arijit
    Bhadauria, Hemant Singh
    Oh, Mok
    Skaltsa, Konstantina
    Tombal, Bertrand
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
    George, Daniel J.
    Khan, Nasreen
    Constantinovici, Niculae
    Khan, Javeed
    Chen, Guifang
    Xu, Julie
    Ortiz, Jorge A.
    Morgans, Alicia K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345